SBIR/STTR Research Award
A Clinical Decision Support Tool for Electronic Health Records
Award amount
$1,996,828Program and phase
SBIR · Phase IIAward year
2013Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Inflexxion, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- PA12-088
- Topic code
- NIDA
Research abstract
DESCRIPTION (provided by applicant): Substance abuse treatment is often complicated by a client's family, employment, psychiatric, or legal problems. When these co-existing issues are addressed with evidence-based practices (EBPs), outcomes improve. The expansion of EBPs is especially important regarding Medication-Assisted Treatment (MAT), which is the subject of a number of federal and state treatment initiatives. However, despite extensive efforts to educate clinicians through training, the integration of EBPs into clinical settings continues to lag. EBPs are most likely to be implemented if information is available at the point of service. These challenges strongly suggest the need for a technical solution. This proposal seeks to develop a clinical decision support (CDS) system within electronic health records (EHRs) through a collaboration of two companies that have developed a national standing in substance abuse treatment - Inflexxion (Newton, MA) and FEi (Columbia, MD). Inflexxion and FEi are seekingto develop the Behavioral Health Advisory Module (BHAM). This CDS will plug into Web Infrastructure for Treatment Services (WITS), a web-based EHR supported by FEi. By applying advanced statistical techniques (latent class analysis) and data mining to the extensive WITS dataset, we can assess the relationships between client profiles, delivered services, and outcomes. BHAM can identify which profile best fits a client and provide: (1) tailored, evidence-based practice recommendations, and (2) client engagement strategies (which have been shown to improve outcomes). In Phase I, we: completed a model comprised of three profiles of opiate/opioid users; developed an interactive prototype of BHAM; and demonstrated acceptance of the CDS concept by substance abuse experts and clinicians. The concept was also reviewed and supported by CDS and substance abuse expert consultants. The goal of Phase II is to fully develop and test BHAM in substance abuse treatment centers. The field test will examine the primary hypotheses that, relative to the Control condition, counselors in treatment facilities assigned to the BHAM program will provide or offer their clients significantly greater matched evidence-based and wraparound services. We will also examine the extent to whichclients being treated by counselors in the Experimental condition, relative to the Control Condition, demonstrate significantly: (1) greater engagement in treatment, (2) fewer alcohol/drug relapses, and (3) greater psychosocial functioning. And finally, we will examine the cost effectiveness of BHAM. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: The public health potential of this project is very significant, and will shift the paradigm away from an asynchronous, training-based, evidence-based practice (EBP) implementation model, to a data-driven, continuing care model. The Behavioral Health Advisory Module (BHAM) can help serve the critical public health goal of overcoming barriers to the implementation of EBPs. It can also assist substanceabusers in maintaining their engagement with treatment and achieving better overall outcomes.
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Wearable Wireless Respiratory Monitoring System that Detects and Predicts Opioid Induced Respiratory Depression
- Building and testing the Life Enhancement and Advocacy Programming digital training tool (LEAPLink) to better serve people with lived experience of homelessness and substance use disorder
- A digital intervention to decrease self-stigma among pregnant and postpartum women with opioid use disorder
- Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting.
- Creation and Validation of the Dose-Opioid-Source Evaluation tool (DOSE) - a Robust Opioid Use Clinical Outcome Assessment for Qualification as an FDA Medical Device Development Tool (MDDT)